Whitehawk Therapeutics (WHWK) Operating Margin (2018 - 2025)
Whitehawk Therapeutics (WHWK) reported Operating Margin of 212.99% for Q1 2025, up 15152.0% year-over-year from N/an in Q1 2024, and up 18.63% on a QoQ basis from 261.76% in Q4 2024.
Whitehawk Therapeutics (WHWK) has 7 years of Operating Margin data on file, last reported at 212.99% in Q1 2025.
- Quarterly Operating Margin rose 15152.0% year-over-year to 212.99% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 60.53% (up 19909.0% YoY) and the FY2025 annual result came in at 60.53%, up 19909.0% from the prior year.
- Operating Margin climbed to 212.99% in Q1 2025 per WHWK's latest filing, from 261.76% in the prior quarter.
- Across five years, Operating Margin topped out at 113.89% in Q4 2021 and bottomed at 3405.83% in Q1 2021.
- The 5-year median for Operating Margin is 296.0% (2022), against an average of 517.45%.
- Peak annual rise in Operating Margin reached 280705 bps in 2022, while the deepest fall reached 18211 bps in 2022.
- Tracing WHWK's Operating Margin over 5 years: stood at 113.89% in 2021, then plunged by 160 bps to 296.0% in 2022, then gained by 5 bps to 280.02% in 2023, then advanced by 7 bps to 261.76% in 2024, then gained by 19 bps to 212.99% in 2025.
- Per Business Quant, the three latest WHWK Operating Margin figures stand at 212.99% (Q1 2025), 261.76% (Q4 2024), and 185.98% (Q3 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Whitehawk Therapeutics | 312.26 Mn | 189.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -212.99% |
| Dec 31, 2024 | -261.76% |
| Sep 30, 2024 | -185.98% |
| Jun 30, 2024 | -252.21% |
| Mar 31, 2024 | -364.51% |
| Dec 31, 2023 | -280.02% |
| Sep 30, 2023 | -299.53% |
| Jun 30, 2023 | -315.14% |
| Mar 31, 2023 | -286.77% |
| Dec 31, 2022 | -296.00% |
| Sep 30, 2022 | -354.20% |
| Jun 30, 2022 | -534.19% |
| Mar 31, 2022 | -598.79% |
| Dec 31, 2021 | -113.89% |
| Mar 31, 2021 | -3,405.83% |
| Dec 31, 2020 | 60.03% |
| Sep 30, 2020 | -1,152.81% |
| Jun 30, 2020 | 61.71% |
| Dec 31, 2018 | -413,534.42% |
| Sep 30, 2018 | 59.49% |
| Jun 30, 2018 | -452.73% |